SCHEMBL721148

SCHEMBL721148

COC(=O)c1ccc(NC(c2oc3ccc(Cl)nc3c2C)C2CCCCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
EPHX2 P34913 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP2C19 P33261 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
MKNK2 Q9HBH9 1/20 0.38
RCE1 Q9Y256 1/20 0.37
MAPK1 P28482 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34
EPHX1 P07099 1/20 0.34
METAP2 P50579 1/20 0.34
CTSL P07711 1/20 0.34
CTSS P25774 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719583 0.91 RCE1 (0.46) ALDH1A1KMT2ACYP2D6CYP2C9MKNK2
SCHEMBL716365 0.89 NPC1 (0.40) NPC1ALDH1A1SMN1; SMN2EPHX2MEN1
SCHEMBL717537 0.84 RCE1 (0.48) NPC1ALDH1A1SMN1; SMN2EPHX2MEN1
SCHEMBL3395640 0.84 GCG (0.51)
SCHEMBL721650 0.83 GCG (0.37) MKNK2RCE1MAPTHPGDTEAD4
SCHEMBL719205 0.83 MEN1 (0.48) ALDH1A1SMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL718281 0.81 MEN1 (0.35) ALDH1A1MEN1KMT2AMKNK2RCE1
SCHEMBL719113 0.79 RCE1 (0.46) ALDH1A1KMT2ACYP2D6CYP2C9RCE1
SCHEMBL14905708 0.77 NPC1 (0.48) NPC1ALDH1A1SMN1; SMN2EPHX2MEN1
SCHEMBL720765 0.76 MEN1 (0.41) NPC1ALDH1A1SMN1; SMN2EPHX2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885ALDH1A1 504/4885SMN1; SMN2 1051/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885ALDH1A1 504/4885SMN1; SMN2 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.